Gadofosveset
Top View
- Proprietary Name Review(S)
- Use of Prohance® (Gadoteridol) for MRI in Special Patient Populations
- WO 2017/222911 A1 (.Pdf)
- ACR Manual on Contrast Media (2020)
- Gadolinium-Based Layered Double Hydroxide and Graphene Oxide
- Provisional Peer-Reviewed Toxicity Values for Stable (Nonradioactive) Gadolinium (Casrn 7440-54-2) and Soluble Salts
- Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus
- Comprehensive Contrast Policy Page 2 of 25
- Questions & Answers Re NSF and Gadolinium, 26 June 2007
- VASOVIST- Gadofosveset Trisodium Injection Bayer Healthcare, Inc
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Pharmacologyonline 3: 728-781 (2010) Newsletter Bradu and Rossini
- Standards for Intravascular Contrast Administration to Adult Patients
- Version 10.3
- Superparamagnetic Iron Oxide Nanoparticles in Biomedicine
- Safety and Clinical Usefulness of Gadoteric Acid Including Post-Marketing Surveillance
- Public Assessment Report for Paediatric Studies Submitted in Accordance with Article 45 of Regulation (EC) No1901/2006, As Amended
- (12) Patent Application Publication (10) Pub. No.: US 2010/0226943 A1 Brennan Et Al